SPI-1005 for Prevention and Treatment of Tobramycin Induced Ototoxicity

Sound Pharmaceuticals

Status and phase: Completed; Phase 2

Conditions: Ototoxicity

Treatments: Drug: SPI-1005 Ebselen 200mg Capsule x1; Drug: SPI-1005 Ebselen 200mg Capsule x2; Drug: SPI-1005 Ebselen 200mg Capsule x3; Drug: Placebo

Study type: Interventional

Funder types: Other; Industry

Identifiers

NCT02819856

SPI-3005-501

Details and patient eligibility

About

The primary objective of this study is to determine the safety and efficacy of SPI-1005 treatment in CF patients with active pulmonary exacerbation that are receiving an IV course of tobramycin, determined by comparing hearing assessments, spirometry, Pharmacokinetic (PK), Physical Exam, Adverse Events (AEs) and Labs baseline to post-treatment.

The secondary objectives of this study are to determine Pharmacogenomics and Pharmacodynamics of SPI-1005.

Full description

Randomized, double-blind, placebo-controlled study to evaluate the safety, and efficacy of SPI-1005 in Cystic Fibrosis patients with Acute Pulmonary Exacerbation receiving intravenous tobramycin at risk for ototoxicity. All patients will undergo baseline testing and have their severity of lung function, sensorineural hearing loss, tinnitus and vertigo determined before the start of SPI-1005 treatment. SPI-1005 treatment will start within first two days of IV tobramycin treatment and be administered concomitantly. At the end of the 21-day course of SPI-1005 and 28 days following the cessation of SPI-1005, patients will have their hearing loss, tinnitus and vertigo reassessed. Assessments may also include additional audiometric and pulmonary testing, and additional follow-up testing.

Enrollment: 40 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Cystic fibrosis patients about to receive IV tobramycin for acute pulmonary exacerbation.
• Voluntarily consent to participate in the study.
• Females of childbearing potential should be using and committed to continue using one of the following acceptable birth control methods:
• Sexual abstinence (inactivity) for 14 days prior to screening through study completion; or IUD in place for at least 3 months prior to study through study completion; or Barrier method (condom or diaphragm) with spermicide for at least 14 days prior to screening through study completion; or Stable hormonal contraceptive for at least 3 months prior to study through study completion.
• Ability to perform all behavioral tests as indicated.

Exclusion criteria

• Current use or within 60 days prior to study enrollment the following IV ototoxic medications: aminoglycoside antibiotics (gentamicin, tobramycin, amikacin, streptomycin); platinum-containing chemotherapies (cisplatin, carboplatin, oxaliplatin); or loop diuretic (furosemide).
• History of idiopathic sensorineural hearing loss, otosclerosis, or vestibular schwannoma.
• History of middle ear or inner ear surgery.
• Current conductive hearing loss or middle ear effusion.
• Significant cardiovascular, hepatic, renal, hematologic, endocrine, immunologic, or psychiatric disease.
• History of hypersensitivity or idiosyncratic reaction to compounds related to ebselen.
• Participation in another investigational drug or device study within 30 days prior to study enrollment.
• Female patients who are pregnant or breastfeeding.

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Quadruple Blind

---

40 participants in 4 patient groups, including a placebo group

SPI-1000 Capsule 0mg Ebselen Placebo

Placebo Comparator group

Description:

0mg Ebselen SPI-1000 bid po x 21d

Treatment:

Drug: Placebo

SPI-1005 Ebselen 200mg Capsule x1

Experimental group

Description:

200mg SPI-1005 bid po x 21d Low Dose Arm

Treatment:

Drug: SPI-1005 Ebselen 200mg Capsule x1

SPI-1005 Ebselen 200mg Capsule x2

Experimental group

Description:

400mg SPI-1005 bid po x 21d Mid Dose Arm

Treatment:

Drug: SPI-1005 Ebselen 200mg Capsule x2

SPI-1005 Ebselen 200mg Capsule x3

Experimental group

Description:

600mg SPI-1005 bid po x 21d High Dose Arm

Treatment:

Drug: SPI-1005 Ebselen 200mg Capsule x3